
Patent claims


1. A compound of the formula (I)



(I),

in which

R^1 represents a heteroaryl group of the formula



wherein


* denotes the linkage point with the dihydropyrazolone ring,

A in each individual occurrence denotes C-R^4 or N, wherein at most two ring members A represent N at the same time,

and

E denotes O, S or N-R^5,

R^2 represents a heteroaryl group of the formula



wherein

# denotes the linkage point with the dihydropyrazolone ring,

G in each individual occurrence denotes C-R^6 or N, wherein at most two ring members G represent N at the same time,

J denotes O, S or N-R^7

and

L in each individual occurrence denotes C-R^8 or N, wherein at most two ring members L represent N at the same time,

wherein

R^4, R^6 und R^8 are identical or different and in each individual case, independently of one another, represents hydrogen or a substituent chosen from the series consisting of halogen, cyano, nitro, (C_1-C_6)-alkyl, (C_3-C_7)-cycloalkyl, 4- to 10-membered heterocycloalkyl, phenyl, 5- or 6-membered heteroaryl, $-C(=O)-R^9$, $-C(=O)-OR^{10}$, $-C(=O)-NR^{11}R^{12}$, $-O-C(=O)-R^{13}$, $-O-C(=O)-NR^{14}R^{15}$, $-NR^{16}-C(=O)-R^{17}$, $-NR^{18}-C(=O)-OR^{19}$, $-NR^{20}-C(=O)-NR^{21}R^{22}$, $-NR^{23}-SO_2-R^{24}$, $-SO_2-R^{25}$, $-SO_2-NR^{26}R^{27}$, $-OR^{28}$, $-SR^{29}$ and $-NR^{30}R^{31}$, wherein

(*i*) (C_1-C_6)-alkyl in its turn can be substituted once to three times in an identical or different manner by radicals chosen from the series consisting of halogen, cyano, oxo, (C_3-C_7)-cycloalkyl, 4- to 10-membered heterocycloalkyl, phenyl, 5- or 6-membered heteroaryl, $-C(=O)-R^9$, $-C(=O)-OR^{10}$, $-C(=O)-NR^{11}R^{12}$, $-O-C(=O)-R^{13}$, $-O-C(=O)-NR^{14}R^{15}$, $-NR^{16}-C(=O)-R^{17}$, $-NR^{18}-C(=O)-OR^{19}$, $-NR^{20}-C(=O)-NR^{21}R^{22}$, $-NR^{23}-SO_2-R^{24}$, $-SO_2-R^{25}$, $-SO_2-NR^{26}R^{27}$, $-OR^{28}$, $-SR^{29}$ and $-NR^{30}R^{31}$,

wherein the cycloalkyl, heterocycloalkyl, phenyl and heteroaryl radicals mentioned last in their turn can in each case be substituted up to three times in an identical or different manner by halogen, cyano, (C_1-C_4)-alkyl, trifluoromethyl, hydroxyl, (C_1-C_4)-alkoxy, trifluoromethoxy, oxo, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl,

(*ii*) (C_3-C_7)-cycloalkyl, 4- to 10-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl in their turn can in each case be substituted once to three times in an identical or different manner by radicals chosen from the series consisting of (C_1-C_6)-alkyl, halogen, cyano, oxo, $-C(=O)-R^9$, $-C(=O)-OR^{10}$, $-C(=O)-NR^{11}R^{12}$, $-O-C(=O)-R^{13}$, $-O-C(=O)-NR^{14}R^{15}$, $-NR^{16}-C(=O)-$

R^{17}, $-NR^{18}-C(=O)-OR^{19}$, $-NR^{20}-C(=O)-NR^{21}R^{22}$, $-NR^{23}-SO_2-R^{24}$, $-SO_2-R^{25}$, $-SO_2-NR^{26}R^{27}$, $-OR^{28}$, $-SR^{29}$ and $-NR^{30}R^{31}$,

wherein the alkyl radical mentioned last can in its turn be substituted up to three times in an identical or different manner by halogen, cyano, hydroxyl, trifluoromethoxy, (C_1-C_4)-alkoxy, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl, (C_1-C_4)-alkoxycarbonyl, (C_3-C_7)-cycloalkyl, 4- to 7-membered heterocycloalkyl, phenyl and/or 5- or 6-membered heteroaryl,

(iii) R^9, R^{10}, R^{11}, R^{13}, R^{14}, R^{17}, R^{19}, R^{21}, R^{24}, R^{25}, R^{26}, R^{28}, R^{29} and R^{30} independently of one another for each individual occurrence represent a radical chosen from the series consisting of hydrogen, (C_1-C_6)-alkyl, (C_3-C_7)-cycloalkyl, 4- to 10-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl, wherein

(C_3-C_7)-cycloalkyl, 4- to 10-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl in their turn can in each case be substituted up to three times in an identical or different manner by halogen, cyano, (C_1-C_4)-alkyl, trifluoromethyl, hydroxyl, (C_1-C_4)-alkoxy, trifluoromethoxy, oxo, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl

and

(C_1-C_6)-alkyl can be substituted once to three times in an identical or different manner by halogen, cyano, hydroxyl, trifluoromethoxy, (C_1-C_4)-alkoxy, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl, (C_1-C_4)-alkoxycarbonyl, (C_3-C_7)-cycloalkyl, 4- to 7-membered hetero-

cycloalkyl, phenyl and/or 5- or 6-membered heteroaryl,

(*iv*) R^{12}, R^{15}, R^{16}, R^{18}, R^{20}, R^{22}, R^{23}, R^{27} and R^{31} independently of one another for each individual occurrence represent a radical chosen from the series consisting of hydrogen and (C_1-C_6)-alkyl,

wherein (C_1-C_6)-alkyl can be substituted once to three times in an identical or different manner by halogen, cyano, hydroxyl, trifluoromethoxy, (C_1-C_4)-alkoxy, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl,

and/or wherein

(*v*) R^{11} and R^{12}, R^{14} and R^{15}, R^{16} and R^{17}, R^{18} and R^{19}, R^{20} and R^{21}, R^{21} and R^{22}, R^{23} und R^{24}, R^{26} and R^{27} and R^{30} and R^{31} in each case paired together with the atoms to which they are bonded can form a 5- or 6-membered heterocycloalkyl ring, which can be substituted once to three times in an identical or different manner by halogen, cyano, (C_1-C_4)-alkyl, trifluoromethyl, hydroxyl, (C_1-C_4)-alkoxy, trifluoromethoxy, oxo, amino, mono-(C_1-C_4)-alkyl-amino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl,

and

R^5 and R^7 are identical or different and independently of one another represent hydrogen or a substituent chosen from the series consisting of (C_1-C_6)-alkyl, (C_3-C_7)-cycloalkyl, 4- to 7-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl, wherein

(*i*) (C_1-C_6)-alkyl in its turn can be substituted once to three times in an identical or different manner by

radicals chosen from the series consisting of halogen, cyano, oxo, (C_3-C_7)-cycloalkyl, 4- to 7-membered heterocycloalkyl, phenyl, 5- or 6-membered heteroaryl, $-C(=O)-R^9$, $-C(=O)-OR^{10}$, $-C(=O)-NR^{11}R^{12}$, $-O-C(=O)-R^{13}$, $-O-C(=O)-NR^{14}R^{15}$, $-NR^{16}-C(=O)-R^{17}$, $-NR^{18}-C(=O)-OR^{19}$, $-NR^{20}-C(=O)-NR^{21}R^{22}$, $-NR^{23}-SO_2-R^{24}$, $-SO_2-R^{25}$, $-SO_2-NR^{26}R^{27}$, $-OR^{28}$, $-SR^{29}$ and $-NR^{30}R^{31}$,

wherein the cycloalkyl, heterocycloalkyl, phenyl and heteroaryl radicals mentioned last in their turn can in each case be substituted up to three times in an identical or different manner by halogen, cyano, (C_1-C_4)-alkyl, trifluoromethyl, hydroxyl, (C_1-C_4)-alkoxy, trifluoromethoxy, oxo, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl,

and

(*ii*) (C_3-C_7)-cycloalkyl, 4- to 7-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl in their turn can in each case be substituted once to three times in an identical or different manner by radicals chosen from the series consisting of (C_1-C_6)-alkyl, halogen, cyano, oxo, $-C(=O)-R^9$, $-C(=O)-OR^{10}$, $-C(=O)-NR^{11}R^{12}$, $-O-C(=O)-R^{13}$, $-O-C(=O)-NR^{14}R^{15}$, $-NR^{16}-C(=O)-R^{17}$, $-NR^{18}-C(=O)-OR^{19}$, $-NR^{20}-C(=O)-NR^{21}R^{22}$, $-NR^{23}-SO_2-R^{24}$, $-SO_2-R^{25}$, $-SO_2-NR^{26}R^{27}$, $-OR^{28}$, $-SR^{29}$ and $-NR^{30}R^{31}$,

wherein the alkyl radical mentioned last in its turn can be substituted up to three times in an identical or different manner by halogen, cyano, hydroxyl, trifluoromethoxy, (C_1-C_4)-alkoxy, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl, (C_1-C_4)-alkoxycarbonyl, (C_3-C_7)-

cycloalkyl, 4- to 7-membered heterocycloalkyl, phenyl and/or 5- or 6-membered heteroaryl,

wherein

(*a*) R^9, R^{10}, R^{11}, R^{13}, R^{14}, R^{17}, R^{19}, R^{21}, R^{24}, R^{25}, R^{26}, R^{28}, R^{29} and R^{30} independently of one another for each individual occurrence represent a radical chosen from the series consisting of hydrogen, (C_1-C_6)-alkyl, (C_3-C_7)-cycloalkyl, 4- to 7-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl, wherein

(C_3-C_7)-cycloalkyl, 4- to 7-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl in their turn can in each case be substituted up to three times in an identical or different manner by halogen, cyano, (C_1-C_4)-alkyl, trifluoromethyl, hydroxyl, (C_1-C_4)-alkoxy, trifluoromethoxy, oxo, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl

and

(C_1-C_6)-alkyl can be substituted once to three times in an identical or different manner by halogen, cyano, hydroxyl, trifluoromethoxy, (C_1-C_4)-alkoxy, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl, (C_1-C_4)-alkoxycarbonyl, (C_3-C_7)-cycloalkyl, 4- to 7-membered heterocycloalkyl, phenyl and/or 5- or 6-membered heteroaryl,

(*b*) R^{12}, R^{15}, R^{16}, R^{18}, R^{20}, R^{22}, R^{23}, R^{27} and R^{31} independently of one another for each individual occurrence represent a radical chosen from the series consisting of hydrogen and (C_1-C_6)-alkyl,

wherein (C_1-C_6)-alkyl can be substituted once to three times in an identical or different manner by halogen, cyano, hydroxyl, trifluoromethoxy, (C_1-C_4)-alkoxy, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl,

and/or

(*c*) R^{11} and R^{12}, R^{14} and R^{15}, R^{16} and R^{17}, R^{18} and R^{19}, R^{20} and R^{21}, R^{21} and R^{22}, R^{23} und R^{24}, R^{26} and R^{27} and R^{30} and R^{31} in each case paired together with the atoms to which they are bonded can form a 5- or 6-membered heterocycloalkyl ring, which can be substituted once to three times in an identical or different manner by halogen, cyano, (C_1-C_4)-alkyl, trifluoromethyl, hydroxyl, (C_1-C_4)-alkoxy, trifluoromethoxy, oxo, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl,

and

R^3 represents hydrogen, (C_1-C_6)-alkyl or (C_3-C_7)-cycloalkyl,


and their salts, solvates and solvates of the salts,

with the exception of the compounds

1*H*-pyrazol-5-yl)-2*H*-3-pyrazolin-5(1*H*)-one,
3',5-dimethyl-2-phenyl-1'-(4-phenyl-1,3-thiazol-2-yl)-1'*H*,2*H*-3,4'-bipyrazol-5'-ol,
3',5-dimethyl-2-phenyl-1'-(4-thiophen-2-yl-1,3-thiazol-2-yl)-1'*H*,2*H*-3,4'-bipyrazol-5'-ol,
3',5-dimethyl-1'-(4-methyl-1,3-thiazol-2-yl)-2-phenyl-1'*H*,2*H*-3,4'-bipyrazol-5'-ol,
2-(4-chlorophenyl)-3',5-dimethyl-1'-(4-phenyl-1,3-thiazol-2-yl)-1'*H*,2*H*-3,4'-bipyrazol-5'-ol
and
2-*tert*-butyl-1'-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-3',5-dimethyl-1'*H*,2*H*-3,4'-bipyrazol-5'-ol.

2. A compound of the formula (I) as claimed in claim 1, in which

R^1 represents a heteroaryl group of the formula



or

wherein

* denotes the linkage point with the dihydropyrazolone ring,

A in each individual occurrence denotes C-R^4 or N, wherein at most two ring members A represent N at the same time, wherein

R^4 in each individual case, independently of one another, represents hydrogen or a substituent chosen from the series consisting of fluorine, chlorine, bromine, cyano, nitro, (C_1-C_6)-alkyl, hydroxyl, (C_1-C_6)-alkoxy, trifluoromethoxy, amino, mono-(C_1-C_6)-alkylamine, di-(C_1-C_6)-alkylamino, hydroxycarbonyl and (C_1-C_6)-alkoxycarbonyl,


wherein the (C_1-C_6)-alkyl radical mentioned in its turn can be substituted up to three times in an identical or different manner by fluorine, chlorine, bromine, cyano, hydroxyl, trifluoromethoxy, (C_1-C_4)-alkoxy, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl,

and


E denotes O, S or N-R^5, wherein

R^5 represents hydrogen or (C_1-C_6)-alkyl,

R^2 represents a heteroaryl group of the formula



or



wherein

# denotes the linkage point with the dihydropyrazolone ring,

G in each case denotes C-R^6 or N, wherein not more than one of the two ring members G represents N, wherein

R^6 in each individual case, independently of one another, represents hydrogen or a substituent chosen from the series consisting of fluorine, chlorine, bromine, cyano, (C_1-C_6)-alkyl, (C_3-C_6)-cycloalkyl, 4- to 6-membered heterocycloalkyl, phenyl, 5- or 6-membered heteroaryl, -C(=O)-OR^{10}, -C(=O)-$NR^{11}R^{12}$, -O-C(=O)-R^{13}, -O-C(=O)-$NR^{14}R^{15}$, -NR^{16}-C(=O)-R^{17}, -NR^{18}-C(=O)-OR^{19}, -NR^{20}-C(=O)-$NR^{21}R^{22}$, -NR^{23}-SO_2-R^{24}, -OR^{28} and -$NR^{30}R^{31}$, wherein

(*i*). (C_1-C_6)-alkyl in its turn can be substituted once to three times in an identical or different manner by radicals chosen from the series consisting of fluorine, chlorine, bromine, cyano, (C_3-C_6)-cycloalkyl, 4- to 6-membered heterocycloalkyl, phenyl, 5- or 6-membered heteroaryl, -C(=O)-OR^{10}, -C(=O)-$NR^{11}R^{12}$, -O-C(=O)-R^{13}, -O-C(=O)-$NR^{14}R^{15}$, -NR^{16}-C(=O)-R^{17}, -NR^{18}-C(=O)-OR^{19}, -NR^{20}-C(=O)-$NR^{21}R^{22}$, -NR^{23}-SO_2-R^{24}, -OR^{28} and -$NR^{30}R^{31}$,

wherein the cycloalkyl, heterocycloalkyl, phenyl and heteroaryl radicals mentioned last in their turn can in each case be substituted up to twice in an identical or different manner by fluorine, chlorine, bromine, cyano, (C_1-C_4)-alkyl, trifluoromethyl, hydroxyl, (C_1-C_4)-alkoxy, trifluoromethoxy, oxo, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-

alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl,

(*ii*) (C_3-C_6)-cycloalkyl, 4- to 6-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl in their turn can in each case be substituted once or twice in an identical or different manner by fluorine, chlorine, bromine, cyano, (C_1-C_4)-alkyl, trifluoromethyl, hydroxyl, (C_1-C_4)-alkoxy, trifluoromethoxy, oxo, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl,

(*iii*) R^{10}, R^{11}, R^{13}, R^{14}, R^{17}, R^{19}, R^{21}, R^{24}, R^{28} and R^{30} independently of one another for each individual occurrence represent a radical chosen from the series consisting of hydrogen, (C_1-C_6)-alkyl, (C_3-C_6)-cycloalkyl, 4- to 6-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl, wherein

(C_3-C_6)-cycloalkyl, 4- to 6-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl in their turn can in each case be substituted up to three times in an identical or different manner by fluorine, chlorine, bromine, cyano, (C_1-C_4)-alkyl, trifluoromethyl, hydroxyl, (C_1-C_4)-alkoxy, trifluoromethoxy, oxo, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl,

and

(C_1-C_6)-alkyl can be substituted once to three times in an identical or different manner by fluorine, chlorine, bromine, cyano, hydroxyl, trifluoromethoxy, (C_1-C_4)-alkoxy, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl, (C_1-C_4)-alkoxycarbonyl, (C_3-C_6)-cycloalkyl, 4- to 6-membered heterocycloalkyl, phenyl and/or 5- or 6-membered heteroaryl,

(*iv*) R^{12}, R^{15}, R^{16}, R^{18}, R^{20}, R^{22}, R^{23} and R^{31} independently of one another for each individual occurrence represent a radical chosen from the series consisting of hydrogen and (C_1-C_6)-alkyl,

wherein (C_1-C_6)-alkyl can be substituted once or twice in an identical or different manner by fluorine, chlorine, bromine, cyano, hydroxyl, trifluoromethoxy, (C_1-C_4)-alkoxy, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl,

and/or wherein

(*v*) R^{11} and R^{12}, R^{14} and R^{15}, R^{16} and R^{17}, R^{18} and R^{19}, R^{20} and R^{21}, R^{21} and R^{22}, R^{23} und R^{24} and R^{30} and R^{31} in each case paired together with the atoms to which they are bonded can form a 5- or 6-membered heterocycloalkyl ring, which can be substituted once or twice in an identical or different manner by fluorine, chlorine, bromine, cyano, (C_1-C_4)-alkyl, trifluoromethyl, hydroxyl, (C_1-C_4)-alkoxy, trifluoromethoxy, oxo, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl,

and

J denotes O or S,


and

R^3 represents hydrogen or methyl,


and their salts, solvates and solvates of the salts.

3. A compound of the formula (I) as claimed in claim 1, in which

R^1 represents a heteroaryl group of the formula



or



wherein

* denotes the linkage point with the dihydropyrazolone ring,

A in each individual occurrence denotes C-R^4 or N, wherein at most one of the ring members A represents N, wherein


R^4 in each individual case, independently of one another, represents hydrogen or a substituent chosen from the series consisting of fluorine, chlorine, bromine, cyano, nitro, (C_1-C_6)-alkyl, hydroxyl, (C_1-C_6)-alkoxy, trifluoromethoxy, amino, mono-(C_1-C_6)-alkylamine, di-(C_1-C_6)-alkylamino, hydroxycarbonyl and (C_1-C_6)-alkoxycarbonyl,

wherein the (C_1-C_6)-alkyl radical mentioned in its turn can be substituted up to three times in an identical or different manner by fluorine, hydroxyl, trifluoromethoxy, (C_1-C_4)-alkoxy, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl,


and

E denotes O or S,

R^2 represents a heteroaryl group of the formula



or



wherein

# denotes the linkage point with the dihydropyrazolone ring,

G in each case denotes C-R^6 or N, wherein not more than one of the two ring members G represents N, wherein

R^6 in each individual case, independently of one another, represents hydrogen or a substituent chosen from the series consisting of fluorine, chlorine, bromine, cyano, (C_1-C_6)-alkyl, (C_3-C_6)-cycloalkyl, 4- to 6-membered heterocycloalkyl, phenyl, 5- or 6-membered heteroaryl, $-C(=O)-OR^{10}$, $-C(=O)-NR^{11}R^{12}$, $-NR^{16}-C(=O)-R^{17}$, $-NR^{18}-C(=O)-ONR^{19}$, $-OR^{28}$ and $-NR^{30}R^{31}$, wherein

(*i*) (C_1-C_6)-alkyl in its turn can be substituted once to three times in an identical or different manner by radicals chosen from the series consisting of fluorine, (C_3-C_6)-cycloalkyl, 4- to 6-membered heterocycloalkyl, 5- or 6-membered heteroaryl, $-C(=O)-OR^{10}$, $-C(=O)-NR^{11}R^{12}$, $-NR^{16}-C(=O)-R^{17}$, $-NR^{18}-C(=O)-OR^{19}$, $-OR^{28}$ and $-NR^{30}R^{31}$,

wherein the cycloalkyl, heterocycloalkyl and heteroaryl radicals mentioned last in their turn can in each case be substituted up to twice in an identical or different manner by fluorine, chlorine, bromine, cyano, (C_1-C_4)-alkyl, trifluoromethyl, hydroxyl, (C_1-C_4)-alkoxy, trifluoromethoxy, oxo, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl,

(*ii*) (C_3-C_6)-cycloalkyl, 4- to 6-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl in their turn can in each case be substituted once or twice in an identical or different manner by fluorine, chlorine, bromine, cyano, (C_1-C_6)-alkyl, hydroxyl, (C_1-C_4)-alkoxy, trifluoromethoxy, oxo, amino, mono-(C_1-C_4)-alkylamino,

di-(C_1-C_4)-alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl,

wherein (C_1-C_6)-alkyl in its turn can be substituted up to three times in an identical or different manner by fluorine, hydroxyl, (C_1-C_4)-alkoxy, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl, (C_1-C_4)-alkoxycarbonyl, (C_3-C_6)-cycloalkyl, 4- to 6-membered heterocycloalkyl, phenyl and/or 5- or 6-membered heteroaryl,

(*iii*) R^{10}, R^{11}, R^{17}, R^{19}, R^{28} and R^{30} independently of one another for each individual occurrence represent a radical chosen from the series consisting of hydrogen, (C_1-C_6)-alkyl, (C_3-C_6)-cycloalkyl and 4- to 6-membered heterocycloalkyl, wherein

(C_3-C_6)-cycloalkyl and 4- to 6-membered heterocycloalkyl in their turn can in each case be substituted up to three times in an identical or different manner by fluorine, (C_1-C_4)-alkyl, trifluoromethyl, hydroxyl, (C_1-C_4)-alkoxy, oxo, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl

and

(C_1-C_6)-alkyl can be substituted once to three times in an identical or different manner by fluorine, hydroxyl, (C_1-C_4)-alkoxy, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl, (C_1-C_4)-alkoxycarbonyl, (C_3-C_6)-cycloalkyl, 4- to 6-membered heterocycloalkyl, phenyl and/or 5- or 6-membered heteroaryl,

(*iv*) R^{12}, R^{16}, R^{18} and R^{31} independently of one another for each individual occurrence represent a radical

chosen from the series consisting of hydrogen and (C_1-C_6)-alkyl,

wherein (C_1-C_6)-alkyl can be substituted once or twice in an identical or different manner by fluorine, hydroxyl, (C_1-C_4)-alkoxy, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl,

and/or wherein

(v) R^{11} and R^{12}, R^{16} and R^{17}, R^{18} and R^{19} and R^{30} and R^{31} in each case paired together with the atoms to which they are bonded can form a 5- or 6-membered heterocycloalkyl ring, which can be substituted once or twice in an identical or different manner by fluorine, (C_1-C_4)-alkyl, trifluoromethyl, hydroxyl, (C_1-C_4)-alkoxy, oxo, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl,

and

J denotes O or S,


and

R^3 represents hydrogen,


and their salts, solvates and solvates of the salts.

4. A compound of the formula (I) as claimed in claim 1, 2 or 3, in which

R^1 represents a heteroaryl group of the formula



or




wherein

* denotes the linkage point with the dihydropyrazolone ring

and

R^4 denotes hydrogen, fluorine, chlorine, bromine, cyano, (C_1-C_4)-alkyl, trifluoromethyl, hydroxymethyl, (C_1-C_4)-alkoxy, trifluoromethoxy, hydroxycarbonyl or (C_1-C_4)-alkoxycarbonyl,

R^2 represents a heteroaryl group of the formula



or

wherein

\# denotes the linkage point with the dihydropyrazolone ring

and

R^6, R^{6A} and R^{6B} are identical or different and independently of one another denote hydrogen or a substituent chosen from the series consisting of fluorine, chlorine, bromine, cyano, (C_1-C_6)-alkyl, trifluoromethyl, hydroxyl, (C_1-C_6)-alkoxy, trifluoromethoxy, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl, (C_1-C_4)-alkoxycarbonyl, 4- to 6-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl, wherein

(C_1-C_6)-alkyl in its turn can be substituted by hydroxyl, (C_1-C_4)-alkoxy or amino

and

4- to 6-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl in their turn can in each case be substituted once or twice in an identical or different manner by fluorine, chlorine, bromine, cyano, (C_1-C_4)-alkyl, trifluoromethyl, hydroxyl, (C_1-C_4)-alkoxy, trifluoromethoxy, oxo, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl,


and

R^3 represents hydrogen,

and their salts, solvates and solvates of the salts.

5. A compound of the formula (I) as claimed in claim 1, 2 or 3, in which

R^1 represents a heteroaryl group of the formula




wherein

* denotes the linkage point with the dihydropyrazolone ring


and

R^4 denotes hydrogen, fluorine, chlorine, bromine, cyano, (C_1-C_4)-alkyl, trifluoromethyl, hydroxymethyl, (C_1-C_4)-alkoxy, trifluoromethoxy, hydroxycarbonyl or (C_1-C_4)-alkoxycarbonyl,

R^2 represents a heteroaryl group of the formula



or



wherein

# denotes the linkage point with the dihydropyrazolone ring

and

R^6, R^{6A} and R^{6B} are identical or different and independently of one another denote hydrogen or a substituent chosen from the series consisting of fluorine, chlorine, bromine, cyano, (C_1-C_6)-alkyl, trifluoromethyl, hydroxyl, (C_1-C_6)-alkoxy, trifluoromethoxy, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl, (C_1-C_4)-alkoxycarbonyl and 4- to 6-membered heterocycloalkyl, wherein

(C_1-C_6)-alkyl in its turn can be substituted by hydroxyl, (C_1-C_4)-alkoxy or amino

and


4- to 6-membered heterocycloalkyl in its turn can be substituted once or twice in an identical or different manner by fluorine, cyano, (C_1-C_4)-alkyl, trifluoromethyl, hydroxyl, (C_1-C_4)-alkoxy, oxo, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl,

and

R^3 represents hydrogen,

and their salts, solvates and solvates of the salts.

6. A process for the preparation of a compound of the formula (I) as defined in claims 1 to 5, characterized in that a compound of the formula (II)




(II),

in which R^1 and R^3 in each case have the meanings given in claims 1 to 5 and

Z^1 represents methyl or ethyl,


is reacted in an inert solvent, optionally in the presence of an acid, with a compound of the formula (III)



(III),

in which R^2 has the meaning given in claims 1 to 5,

to give compounds of the formula (IV)




(IV)

in which Z^1, R^1, R^2 and R^3 have the abovementioned meanings,

which cyclize already under these reaction conditions or in a subsequent reaction step under the influence of a base to give the compounds of the formula (I),

and the compounds of the formula (I) are optionally converted with the corresponding (i) solvents and/or (ii) bases or acids into their solvates, salts and/or solvates of the salts.

7. A process for the preparation of a compound of the formula (I) as defined in claims 1 to 5 in which R^3 denotes hydrogen, characterized in that a compound of the formula (V)




(V),

in which R^1 has the meaning given in claims 1 to 5 and

Z^1 represents methyl or ethyl,

is subjected to a condensation reaction with a compound of the formula (VI)




(VI),

in which

Z^2 represents methyl or ethyl,


to give compounds of the formula (VII)



(VII),

in which Z^1 and R^1 have the abovementioned meanings,


and these are subsequently reacted in the presence of an acid with a compound of the formula (III)



(III),

in which R^2 has the meaning given in claims 1 to 5,

to give compounds of the formula (IV-A)



(IV-A)

in which Z^1, R^1 and R^2 have the abovementioned meanings,

which cyclize already under these reaction conditions or in a subsequent reaction step under the influence of a base to give the compounds of the formula (I) wherein R^3 represents hydrogen.

8. A compound as defined in one of claims 1 to 5 for treatment and/or prophylaxis of diseases.


9. The use of a compound as defined in one of claims 1 to 5 for the preparation of a medicament for treatment and/or prophylaxis of cardiovascular diseases, cardiac insufficiency, anemia, chronic kidney diseases and renal insufficiency..

10. A medicament comprising a compound as defined in one of claims 1 to 5 in combination with an inert, non-toxic, pharmaceutically suitable auxiliary substance.

11. A medicament comprising a compound as defined in one of claims 1 to 5 in combination with one or more further active compounds chosen from the group consisting of ACE inhibitors, angiotensin II receptor antagonists, beta receptor blockers, calcium antagonists, PDE inhibitors, mineralocorticoid receptor antagonists, diuretics, aspirin, iron supplements, vitamin B12 and folic acid supplements, statins, digitalis (digoxin) derivatives, tumor chemotherapeutics and antibiotics.


12. A medicament as claimed in claim 10 or 11 for treatment and/or prophylaxis of cardiovascular diseases, cardiac insufficiency, anemia, chronic kidney diseases and renal insufficiency..

13. 2-(6-Morpholin-4-ylpyrimidin-4-yl)-4-(1*H*-1,2,3-triazol-1-yl)-1,2-dihydro-3*H*-pyrazol-3-one according to claim 1 having the following formula




and its salts, solvates and solvates of the salts.


14. 2-(6-Morpholin-4-ylpyrimidin-4-yl)-4-(1*H*-1,2,3-triazol-1-yl)-1,2-dihydro-3*H*-pyrazol-3-one according to claim 1 having the following formula



15. 2-(6-Morpholin-4-ylpyrimidin-4-yl)-4-(1*H*-1,2,3-triazol-1-yl)-1,2-dihydro-3*H*-pyrazol-3-one hydrochloride according to claim 1 having the following formula




16. 2-[5-(Hydroxymethyl)pyridin-2-yl]-4-[4-(trifluoromethyl)-1*H*-imidazol-1-yl]-1,2-dihydro-3*H*-pyrazol-3-one according to claim 1 having the following formula




and its salts, solvates and solvates of the salts.

17. 2-[5-(Hydroxymethyl)pyridin-2-yl]-4-[4-(trifluoromethyl)-1*H*-imidazol-1-yl]-1,2-dihydro-3*H*-pyrazol-3-one according to claim 1 having the following formula




18. 2-[5-(Hydroxymethyl)pyridin-2-yl]-4-[4-(trifluoromethyl)-1*H*-imidazol-1-yl]-1,2-dihydro-3*H*-pyrazol-3-one hydrochloride according to claim 1 having the following formula



CLAIMS


1. A compound of the formula (I)




(I),

in which

R^1 represents a heteroaryl group of the formula



or




wherein

* denotes the linkage point with the dihydropyrazolone ring


and

R^4 denotes hydrogen, fluorine, chlorine, bromine, cyano, $(C_1\text{-}C_4)$-alkyl, trifluoromethyl, hydroxymethyl, $(C_1\text{-}C_4)$-alkoxy, trifluoromethoxy, hydroxycarbonyl or $(C_1\text{-}C_4)$-alkoxycarbonyl,

R^2 represents a heteroaryl group of the formula



or



wherein

# denotes the linkage point with the dihydropyrazolone ring

and

R^6, R^{6A} and R^{6B} are identical or different and independently of one another denote hydrogen or a substituent chosen from the group consisting of fluorine, chlorine, bromine, cyano, (C_1-C_6)-alkyl, trifluoromethyl, hydroxyl, (C_1-C_6)-alkoxy, trifluoromethoxy, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl, (C_1-C_4)-alkoxycarbonyl, 4- to 6-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl, wherein

(C_1-C_6)-alkyl in its turn can be substituted by hydroxyl, (C_1-C_4)-alkoxy or amino

and

4- to 6-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl in their turn can in each case be substituted once or twice in an identical or different manner by fluorine, chlorine, bromine, cyano, (C_1-C_4)-alkyl, trifluoromethyl, hydroxyl, (C_1-C_4)-alkoxy, trifluoromethoxy, oxo, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl ~~and/~~or (C_1-C_4)-alkoxycarbonyl,


and

R^3 represents hydrogen,

or a salt thereof.

2. A method of making a compound of claim 1 comprising:

reacting a compound of the formula (V)




(V),

in which R^1 has the meaning given in claim 1 and

Z^1 represents methyl or ethyl,

in a condensation reaction with a compound of the formula (VI)




(VI),

in which

Z^2 represents methyl or ethyl,


to give a compound of the formula (VII)



(VII),

in which Z^1 represents methyl or ethyl and R^1 has the meaning given in claim 1,


and reacting the compound of formula (VII) in the presence of an acid with a compound of the formula (III)



(III),

in which R^2 has the meaning given in claim 1,

to give compounds of the formula (IV-A)



(IV-A)

in which Z^1 represents methyl or ethyl and R^1 and R^2 have the meanings given in claim 1,


and allowing a compound of formula (IV-A) to cyclize in the final reaction step given above, or cyclizing a compound of formula (IV-A) in a subsequent reaction step under the influence of a base to give a compound of the formula (I).

3. A pharmaceutical composition comprising a compound as defined in claim 1 in combination with an inert, non-toxic, pharmaceutically suitable auxiliary substance.

4. The pharmaceutical composition of claim 3, further comprising an active compound selected from the group consisting of an ACE inhibitor, an angiotensin II receptor antagonist, a beta receptor blocker, a calcium antagonist, a PDE inhibitor, a mineralocorticoid receptor antagonist, a diuretic, aspirin, an iron supplement, a_vitamin B12 supplement, a folic acid supplement, a statin, a digitalis (digoxin) derivative, a tumor chemotherapeutic, and an antibiotic.

5. A compound of the formula (I) as claimed in claim 1, in which

R^1 represents a heteroaryl group of the formula




wherein

* denotes the linkage point with the dihydropyrazolone ring


and

R^4 denotes hydrogen, fluorine, chlorine, bromine, cyano, (C_1-C_4)-alkyl, trifluoromethyl, hydroxymethyl, (C_1-C_4)-alkoxy, trifluoromethoxy, hydroxycarbonyl or (C_1-C_4)-alkoxycarbonyl,

R^2 represents a heteroaryl group of the formula



or



wherein

\# denotes the linkage point with the dihydropyrazolone ring

and

R^6, R^{6A} and R^{6B} are identical or different and independently of one another denote hydrogen or a substituent chosen from the series consisting

of fluorine, chlorine, bromine, cyano, (C_1-C_6)-alkyl, trifluoromethyl, hydroxyl, (C_1-C_6)-alkoxy, trifluoromethoxy, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl, (C_1-C_4)-alkoxycarbonyl, 4- to 6-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl, wherein

(C_1-C_6)-alkyl in its turn can be substituted by hydroxyl, (C_1-C_4)-alkoxy or amino

and

4- to 6-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl in their turn can in each case be substituted once or twice in an identical or different manner by fluorine, chlorine, bromine, cyano, (C_1-C_4)-alkyl, trifluoromethyl, hydroxyl, (C_1-C_4)-alkoxy, trifluoromethoxy, oxo, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl,


and

R^3 represents hydrogen,


or a salt thereof.

6. A compound of the formula (I) as claimed in claim 1, in which

R^1 represents a heteroaryl group of the formula



or




wherein

* denotes the linkage point with the dihydropyrazolone ring

and

R^4 denotes hydrogen, fluorine, chlorine, bromine, cyano, (C_1-C_4)-alkyl, trifluoromethyl, hydroxymethyl, (C_1-C_4)-alkoxy, trifluoromethoxy, hydroxycarbonyl or (C_1-C_4)-alkoxycarbonyl,

R^2 represents a heteroaryl group of the formula



wherein

\# denotes the linkage point with the dihydropyrazolone ring

and

R^6 denotes hydrogen or a substituent chosen from the series consisting of fluorine, chlorine, bromine, cyano, (C_1-C_6)-alkyl, trifluoromethyl, hydroxyl, (C_1-C_6)-alkoxy, trifluoromethoxy, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl, (C_1-C_4)-alkoxycarbonyl, 4- to 6-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl, wherein

(C_1-C_6)-alkyl in its turn can be substituted by hydroxyl, (C_1-C_4)-alkoxy or amino

and

4- to 6-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl in their turn can in each case be substituted once or twice in an identical or different manner by fluorine, chlorine, bromine, cyano, (C_1-C_4)-alkyl, trifluoromethyl, hydroxyl, (C_1-C_4)-alkoxy, trifluoromethoxy, oxo, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl,


and

R^3 represents hydrogen,

or a salt thereof.

7. A compound of claim 1, in which

R^1 represents a heteroaryl group of the formula




wherein

* denotes the linkage point with the dihydropyrazolone ring

and

R^4 denotes hydrogen, fluorine, chlorine, bromine, cyano, (C_1-C_4)-alkyl, trifluoromethyl, hydroxymethyl, (C_1-C_4)-alkoxy, trifluoromethoxy, hydroxycarbonyl or (C_1-C_4)-alkoxycarbonyl,

R^2 represents a heteroaryl group of the formula



wherein

# denotes the linkage point with the dihydropyrazolone ring

and

R^6 denotes hydrogen or a substituent chosen from the series consisting of fluorine, chlorine, bromine, cyano, (C_1-C_6)-alkyl, trifluoromethyl, hydroxyl, (C_1-C_6)-alkoxy, trifluoromethoxy, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl, (C_1-C_4)-alkoxycarbonyl, 4- to 6-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl, wherein

(C_1-C_6)-alkyl in its turn can be substituted by hydroxyl, (C_1-C_4)-alkoxy or amino

and


4- to 6-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl in their turn can in each case be substituted once or twice in an identical or different manner by fluorine, chlorine, bromine, cyano, (C_1-C_4)-alkyl, trifluoromethyl, hydroxyl, (C_1-C_4)-alkoxy, trifluoromethoxy, oxo, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl,

and

R^3 represents hydrogen,


or a salt thereof.

8. 2-(6-Morpholin-4-ylpyrimidin-4-yl)-4-(1*H*-1,2,3-triazol-1-yl)-1,2-dihydro-3*H*-pyrazol-3-one, a compound having the following formula




or a salt thereof.


9. The compound of claim 8, wherein the compound is 2-(6-Morpholin-4-ylpyrimidin-4-yl)-4-(1*H*-1,2,3-triazol-1-yl)-1,2-dihydro-3*H*-pyrazol-3-one having the following formula



10. A salt of the compound of claim 8, wherein the salt is 2-(6-Morpholin-4-ylpyrimidin-4-yl)-4-(1*H*-1,2,3-triazol-1-yl)-1,2-dihydro-3*H*-pyrazol-3-one hydrochloride having the following formula




11. A compound of the formula (I)



(I),

in which

R^1 represents a heteroaryl group of the formula



wherein


* denotes the linkage point with the dihydropyrazolone ring,


A in each individual occurrence denotes C-R^4 or N, wherein at most two ring members A represent N at the same time,


and


E denotes O, S or N-R^5,


R^2 represents a heteroaryl group of the formula





,



,



,



,



,



,



,


,


,


,


,


or


wherein

# denotes the linkage point with the dihydropyrazolone ring,

G in each individual occurrence denotes C-R^6 or N, wherein at most two ring members G represent N at the same time,

J denotes O, S or N-R^7

and

L in each individual occurrence denotes C-R^8 or N, wherein at most two ring members L represent N at the same time,

wherein

R^4, R^6 und R^8 are identical or different and in each individual case, independently of one another, represents hydrogen or a substituent chosen from the series consisting of halogen, cyano, nitro, (C_1-C_6)-alkyl, (C_3-C_7)-cycloalkyl, 4- to 10-membered heterocycloalkyl, phenyl, 5- or 6-membered heteroaryl, -C(=O)-R^9, -C(=O)-OR^{10}, -C(=O)-$NR^{11}R^{12}$, -O-C(=O)-R^{13}, -O-C(=O)-$NR^{14}R^{15}$, -NR^{16}-C(=O)-R^{17}, -NR^{18}-C(=O)-OR^{19}, -NR^{20}-C(=O)-$NR^{21}R^{22}$, -NR^{23}-SO_2-R^{24}, -SO_2-R^{25}, -SO_2-$NR^{26}R^{27}$, -OR^{28}, -SR^{29} and -$NR^{30}R^{31}$, wherein

(*i*) (C_1-C_6)-alkyl in its turn can be substituted once to three times in an identical or different manner by radicals chosen from the series consisting of halogen, cyano, oxo, (C_3-C_7)-cycloalkyl, 4- to 10-membered heterocycloalkyl, phenyl, 5- or 6-membered heteroaryl, -C(=O)-R^9, -C(=O)-OR^{10}, -C(=O)-$NR^{11}R^{12}$, -O-C(=O)-R^{13}, -O-C(=O)-$NR^{14}R^{15}$, -NR^{16}-C(=O)-R^{17}, -NR^{18}-C(=O)-OR^{19}, -NR^{20}-

$C(=O)-NR^{21}R^{22}$, $-NR^{23}-SO_2-R^{24}$, $-SO_2-R^{25}$, $-SO_2-NR^{26}R^{27}$, $-OR^{28}$, $-SR^{29}$ and $-NR^{30}R^{31}$,

wherein the cycloalkyl, heterocycloalkyl, phenyl and heteroaryl radicals mentioned last in their turn can in each case be substituted up to three times in an identical or different manner by halogen, cyano, (C_1-C_4)-alkyl, trifluoromethyl, hydroxyl, (C_1-C_4)-alkoxy, trifluoromethoxy, oxo, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl,

(*ii*) (C_3-C_7)-cycloalkyl, 4- to 10-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl in their turn can in each case be substituted once to three times in an identical or different manner by radicals chosen from the series consisting of (C_1-C_6)-alkyl, halogen, cyano, oxo, $-C(=O)-R^9$, $-C(=O)-OR^{10}$, $-C(=O)-NR^{11}R^{12}$, $-O-C(=O)-R^{13}$, $-O-C(=O)-NR^{14}R^{15}$, $-NR^{16}-C(=O)-R^{17}$, $-NR^{18}-C(=O)-OR^{19}$, $-NR^{20}-C(=O)-NR^{21}R^{22}$, $-NR^{23}-SO_2-R^{24}$, $-SO_2-R^{25}$, $-SO_2-NR^{26}R^{27}$, $-OR^{28}$, $-SR^{29}$ and $-NR^{30}R^{31}$,

wherein the alkyl radical mentioned last can in its turn be substituted up to three times in an identical or different manner by halogen, cyano, hydroxyl, trifluoromethoxy, (C_1-C_4)-alkoxy, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl, (C_1-C_4)-alkoxycarbonyl, (C_3-C_7)-cycloalkyl, 4- to 7-membered heterocycloalkyl, phenyl and/or 5- or 6-membered heteroaryl,

(*iii*) R^9, R^{10}, R^{11}, R^{13}, R^{14}, R^{17}, R^{19}, R^{21}, R^{24}, R^{25}, R^{26}, R^{28}, R^{29} and R^{30} independently of one another for each individual occurrence represent a radical chosen from the series consisting of hydrogen, (C_1-C_6)-alkyl, (C_3-C_7)-cycloalkyl, 4- to 10-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl, wherein

(C_3-C_7)-cycloalkyl, 4- to 10-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl in their turn can in each case be substituted up to three times in an identical or different manner by halogen, cyano, (C_1-C_4)-alkyl, trifluoromethyl, hydroxyl, (C_1-C_4)-alkoxy, trifluoromethoxy, oxo, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl

and

(C_1-C_6)-alkyl can be substituted once to three times in an identical or different manner by halogen, cyano, hydroxyl, trifluoromethoxy, (C_1-C_4)-alkoxy, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl, (C_1-C_4)-alkoxycarbonyl, (C_3-C_7)-cycloalkyl, 4- to 7-membered heterocycloalkyl, phenyl and/or 5- or 6-membered heteroaryl,

(*iv*) R^{12}, R^{15}, R^{16}, R^{18}, R^{20}, R^{22}, R^{23}, R^{27} and R^{31} independently of one another for each individual occurrence represent a radical chosen from the series consisting of hydrogen and (C_1-C_6)-alkyl,

wherein (C_1-C_6)-alkyl can be substituted once to three times in an identical or different manner by halogen, cyano, hydroxyl, trifluoromethoxy, (C_1-C_4)-alkoxy, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl,

and/or wherein

(*v*) R^{11} and R^{12}, R^{14} and R^{15}, R^{16} and R^{17}, R^{18} and R^{19}, R^{20} and R^{21}, R^{21} and R^{22}, R^{23} und R^{24}, R^{26} and R^{27} and R^{30} and R^{31} in each case paired together with the atoms to which they are bonded can form a 5- or 6-membered heterocycloalkyl ring, which can be substituted once to three times in an identical or different manner by halogen, cyano, (C_1-C_4)-alkyl, trifluoromethyl, hydroxyl, (C_1-C_4)-alkoxy, trifluoromethoxy, oxo, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl,

and

R^5 and R^7 are identical or different and independently of one another represent hydrogen or a substituent chosen from the series consisting of (C_1-C_6)-alkyl, (C_3-C_7)-cycloalkyl, 4- to 7-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl, wherein

(*i*) (C_1-C_6)-alkyl in its turn can be substituted once to three times in an identical or different manner by radicals chosen from the series consisting of halogen, cyano, oxo, (C_3-C_7)-cycloalkyl, 4- to 7-membered heterocycloalkyl, phenyl, 5- or 6-

membered heteroaryl, -C(=O)-R^9, -C(=O)-OR^{10}, -C(=O)-$NR^{11}R^{12}$, -O-C(=O)-R^{13}, -O-C(=O)-$NR^{14}R^{15}$, -NR^{16}-C(=O)-R^{17}, -NR^{18}-C(=O)-OR^{19}, -NR^{20}-C(=O)-$NR^{21}R^{22}$, -NR^{23}-SO_2-R^{24}, -SO_2-R^{25}, -SO_2-$NR^{26}R^{27}$, -OR^{28}, -SR^{29} and -$NR^{30}R^{31}$,

wherein the cycloalkyl, heterocycloalkyl, phenyl and heteroaryl radicals mentioned last in their turn can in each case be substituted up to three times in an identical or different manner by halogen, cyano, (C_1-C_4)-alkyl, trifluoromethyl, hydroxyl, (C_1-C_4)-alkoxy, trifluoromethoxy, oxo, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl,

and

(*ii*) (C_3-C_7)-cycloalkyl, 4- to 7-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl in their turn can in each case be substituted once to three times in an identical or different manner by radicals chosen from the series consisting of (C_1-C_6)-alkyl, halogen, cyano, oxo, -C(=O)-R^9, -C(=O)-OR^{10}, -C(=O)-$NR^{11}R^{12}$, -O-C(=O)-R^{13}, -O-C(=O)-$NR^{14}R^{15}$, -NR^{16}-C(=O)-R^{17}, -NR^{18}-C(=O)-OR^{19}, -NR^{20}-C(=O)-$NR^{21}R^{22}$, -NR^{23}-SO_2-R^{24}, -SO_2-R^{25}, -SO_2-$NR^{26}R^{27}$, -OR^{28}, -SR^{29} and -$NR^{30}R^{31}$,

wherein the alkyl radical mentioned last in its turn can be substituted up to three times in an identical or different manner by halogen, cyano, hydroxyl, trifluoromethoxy, (C_1-C_4)-alkoxy, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino,

hydroxycarbonyl, (C_1-C_4)-alkoxycarbonyl, (C_3-C_7)-cycloalkyl, 4- to 7-membered heterocycloalkyl, phenyl and/or 5- or 6-membered heteroaryl,

wherein

(*a*) R^9, R^{10}, R^{11}, R^{13}, R^{14}, R^{17}, R^{19}, R^{21}, R^{24}, R^{25}, R^{26}, R^{28}, R^{29} and R^{30} independently of one another for each individual occurrence represent a radical chosen from the series consisting of hydrogen, (C_1-C_6)-alkyl, (C_3-C_7)-cycloalkyl, 4- to 7-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl, wherein

(C_3-C_7)-cycloalkyl, 4- to 7-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl in their turn can in each case be substituted up to three times in an identical or different manner by halogen, cyano, (C_1-C_4)-alkyl, trifluoromethyl, hydroxyl, (C_1-C_4)-alkoxy, trifluoromethoxy, oxo, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl

and

(C_1-C_6)-alkyl can be substituted once to three times in an identical or different manner by halogen, cyano, hydroxyl, trifluoromethoxy, (C_1-C_4)-alkoxy, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl, (C_1-C_4)-alkoxycarbonyl, (C_3-C_7)-cycloalkyl, 4- to 7-membered heterocycloalkyl, phenyl and/or 5- or 6-membered heteroaryl,

(*b*) R^{12}, R^{15}, R^{16}, R^{18}, R^{20}, R^{22}, R^{23}, R^{27} and R^{31} independently of one another for each individual occurrence represent a radical chosen from the series consisting of hydrogen and (C_1-C_6)-alkyl,

wherein (C_1-C_6)-alkyl can be substituted once to three times in an identical or different manner by halogen, cyano, hydroxyl, trifluoromethoxy, (C_1-C_4)-alkoxy, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl,

and/or

(*c*) R^{11} and R^{12}, R^{14} and R^{15}, R^{16} and R^{17}, R^{18} and R^{19}, R^{20} and R^{21}, R^{21} and R^{22}, R^{23} und R^{24}, R^{26} and R^{27} and R^{30} and R^{31} in each case paired together with the atoms to which they are bonded can form a 5- or 6-membered heterocycloalkyl ring, which can be substituted once to three times in an identical or different manner by halogen, cyano, (C_1-C_4)-alkyl, trifluoromethyl, hydroxyl, (C_1-C_4)-alkoxy, trifluoromethoxy, oxo, amino, mono-(C_1-C_4)-alkyl-amino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl,

and

R^3 represents hydrogen, (C_1-C_6)-alkyl or (C_3-C_7)-cycloalkyl,


and their salts, solvates and solvates of the salts,

with the exception of the compounds


3-methyl-1-(pyridin-2-yl)-4-(1-pyridin-2-yl-3-methyl-1*H*-pyrazol-5-yl)-2*H*-3-pyrazolin-5(1*H*)-one,
3',5-dimethyl-2-phenyl-1'-(4-phenyl-1,3-thiazol-2-yl)-1'*H*,2*H*-3,4'-bipyrazol-5'-ol,
3',5-dimethyl-2-phenyl-1'-(4-thiophen-2-yl-1,3-thiazol-2-yl)-1'*H*,2*H*-3,4'-bipyrazol-5'-ol,
3',5-dimethyl-1'-(4-methyl-1,3-thiazol-2-yl)-2-phenyl-1'*H*,2*H*-3,4'-bipyrazol-5'-ol,
2-(4-chlorophenyl)-3',5-dimethyl-1'-(4-phenyl-1,3-thiazol-2-yl)-1'*H*,2*H*-3,4'-bipyrazol-5'-ol
and
2-*tert*-butyl-1'-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-3',5-dimethyl-1'*H*,2*H*-3,4'-bipyrazol-5'-ol.

12. A compound of the formula (I) as claimed in claim 11, in which

R^1 represents a heteroaryl group of the formula



or



wherein

* denotes the linkage point with the dihydropyrazolone ring,

A in each individual occurrence denotes C-R^4 or N, wherein at most two ring members A represent N at the same time, wherein

R^4 in each individual case, independently of one another, represents hydrogen or a substituent chosen from the series consisting of fluorine, chlorine, bromine, cyano, nitro, (C_1-C_6)-alkyl, hydroxyl, (C_1-C_6)-alkoxy, trifluoromethoxy,

amino, mono-(C_1-C_6)-alkylamine, di-(C_1-C_6)-alkylamino, hydroxycarbonyl and (C_1-C_6)-alkoxycarbonyl,


wherein the (C_1-C_6)-alkyl radical mentioned in its turn can be substituted up to three times in an identical or different manner by fluorine, chlorine, bromine, cyano, hydroxyl, trifluoromethoxy, (C_1-C_4)-alkoxy, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl,

and


E denotes O, S or N-R^5, wherein

R^5 represents hydrogen or (C_1-C_6)-alkyl,

R^2 represents a heteroaryl group of the formula



or



wherein

# denotes the linkage point with the dihydropyrazolone ring,

G in each case denotes C-R^6 or N, wherein not more than one of the two ring members G represents N, wherein

R^6 in each individual case, independently of one another, represents hydrogen or a substituent chosen from the series consisting of fluorine, chlorine, bromine, cyano, (C_1-C_6)-alkyl, (C_3-C_6)-cycloalkyl, 4- to 6-membered

heterocycloalkyl, phenyl, 5- or 6-membered heteroaryl, $-C(=O)-OR^{10}$, $-C(=O)-NR^{11}R^{12}$, $-O-C(=O)-R^{13}$, $-O-C(=O)-NR^{14}R^{15}$, $-NR^{16}-C(=O)-R^{17}$, $-NR^{18}-C(=O)-OR^{19}$, $-NR^{20}-C(=O)-NR^{21}R^{22}$, $-NR^{23}-SO_2-R^{24}$, $-OR^{28}$ and $-NR^{30}R^{31}$, wherein

(*i*) (C_1-C_6)-alkyl in its turn can be substituted once to three times in an identical or different manner by radicals chosen from the series consisting of fluorine, chlorine, bromine, cyano, (C_3-C_6)-cycloalkyl, 4- to 6-membered heterocycloalkyl, phenyl, 5- or 6-membered heteroaryl, $-C(=O)-OR^{10}$, $-C(=O)-NR^{11}R^{12}$, $-O-C(=O)-R^{13}$, $-O-C(=O)-NR^{14}R^{15}$, $-NR^{16}-C(=O)-R^{17}$, $-NR^{18}-C(=O)-OR^{19}$, $-NR^{20}-C(=O)-NR^{21}R^{22}$, $-NR^{23}-SO_2-R^{24}$, $-OR^{28}$ and $-NR^{30}R^{31}$,

wherein the cycloalkyl, heterocycloalkyl, phenyl and heteroaryl radicals mentioned last in their turn can in each case be substituted up to twice in an identical or different manner by fluorine, chlorine, bromine, cyano, (C_1-C_4)-alkyl, trifluoromethyl, hydroxyl, (C_1-C_4)-alkoxy, trifluoromethoxy, oxo, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl,

(*ii*) (C_3-C_6)-cycloalkyl, 4- to 6-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl in their turn can in each case be substituted once or twice in an identical or different manner by fluorine, chlorine, bromine, cyano, (C_1-C_4)-alkyl, trifluoromethyl, hydroxyl, (C_1-C_4)-alkoxy, trifluoromethoxy, oxo, amino, mono-$(C_1-$

C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl,

(*iii*) R^{10}, R^{11}, R^{13}, R^{14}, R^{17}, R^{19}, R^{21}, R^{24}, R^{28} and R^{30} independently of one another for each individual occurrence represent a radical chosen from the series consisting of hydrogen, (C_1-C_6)-alkyl, (C_3-C_6)-cycloalkyl, 4- to 6-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl, wherein

(C_3-C_6)-cycloalkyl, 4- to 6-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl in their turn can in each case be substituted up to three times in an identical or different manner by fluorine, chlorine, bromine, cyano, (C_1-C_4)-alkyl, trifluoromethyl, hydroxyl, (C_1-C_4)-alkoxy, trifluoromethoxy, oxo, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl,

and

(C_1-C_6)-alkyl can be substituted once to three times in an identical or different manner by fluorine, chlorine, bromine, cyano, hydroxyl, trifluoromethoxy, (C_1-C_4)-alkoxy, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl, (C_1-C_4)-alkoxycarbonyl, (C_3-C_6)-cycloalkyl, 4- to 6-membered heterocycloalkyl, phenyl and/or 5- or 6-membered heteroaryl,

(*iv*) R^{12}, R^{15}, R^{16}, R^{18}, R^{20}, R^{22}, R^{23} and R^{31} independently of one another for each individual occurrence represent a radical chosen from the series consisting of hydrogen and (C_1-C_6)-alkyl,

wherein (C_1-C_6)-alkyl can be substituted once or twice in an identical or different manner by fluorine, chlorine, bromine, cyano, hydroxyl, trifluoromethoxy, (C_1-C_4)-alkoxy, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl,

and/or wherein

(*v*) R^{11} and R^{12}, R^{14} and R^{15}, R^{16} and R^{17}, R^{18} and R^{19}, R^{20} and R^{21}, R^{21} and R^{22}, R^{23} und R^{24} and R^{30} and R^{31} in each case paired together with the atoms to which they are bonded can form a 5- or 6-membered heterocycloalkyl ring, which can be substituted once or twice in an identical or different manner by fluorine, chlorine, bromine, cyano, (C_1-C_4)-alkyl, trifluoromethyl, hydroxyl, (C_1-C_4)-alkoxy, trifluoromethoxy, oxo, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl,

and

J denotes O or S,


and

R^3 represents hydrogen or methyl,

and their salts, solvates and solvates of the salts.

13. A compound of the formula (I) as claimed in claim 11, in which

R^1 represents a heteroaryl group of the formula



wherein

* denotes the linkage point with the dihydropyrazolone ring,

A in each individual occurrence denotes C-R^4 or N, wherein at most one of the ring members A represents N, wherein


R^4 in each individual case, independently of one another, represents hydrogen or a substituent chosen from the series consisting of fluorine, chlorine, bromine, cyano, nitro, (C_1-C_6)-alkyl, hydroxyl, (C_1-C_6)-alkoxy, trifluoromethoxy, amino, mono-(C_1-C_6)-alkylamine, di-(C_1-C_6)-alkylamino, hydroxycarbonyl and (C_1-C_6)-alkoxycarbonyl,

wherein the (C_1-C_6)-alkyl radical mentioned in its turn can be substituted up to three times in an identical or different manner by fluorine, hydroxyl, trifluoromethoxy, (C_1-C_4)-alkoxy, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkyl-amino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl,


and

E denotes O or S,

R^2 represents a heteroaryl group of the formula



or



wherein

# denotes the linkage point with the dihydropyrazolone ring,

G in each case denotes C-R^6 or N, wherein not more than one of the two ring members G represents N, wherein

R^6 in each individual case, independently of one another, represents hydrogen or a substituent chosen from the series consisting of fluorine, chlorine, bromine, cyano, (C_1-C_6)-alkyl, (C_3-C_6)-cycloalkyl, 4- to 6-membered heterocycloalkyl, phenyl, 5- or 6-membered heteroaryl, $-C(=O)-OR^{10}$, $-C(=O)-NR^{11}R^{12}$, $-NR^{16}-C(=O)-R^{17}$, $-NR^{18}-C(=O)-ONR^{19}$, $-OR^{28}$ and $-NR^{30}R^{31}$, wherein

(*i*) (C_1-C_6)-alkyl in its turn can be substituted once to three times in an identical or different manner by radicals chosen from the series consisting of fluorine, (C_3-C_6)-cycloalkyl, 4- to 6-membered heterocycloalkyl, 5- or 6-membered heteroaryl, $-C(=O)-OR^{10}$, $-C(=O)-NR^{11}R^{12}$, $-NR^{16}-C(=O)-R^{17}$, $-NR^{18}-C(=O)-OR^{19}$, $-OR^{28}$ and $-NR^{30}R^{31}$,

wherein the cycloalkyl, heterocycloalkyl and heteroaryl radicals mentioned last in their turn can in each case be substituted up to twice in an identical or different manner by fluorine, chlorine, bromine, cyano, (C_1-C_4)-alkyl, trifluoromethyl, hydroxyl, (C_1-C_4)-alkoxy, trifluoromethoxy, oxo,

amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl,

(*ii*) (C_3-C_6)-cycloalkyl, 4- to 6-membered heterocycloalkyl, phenyl and 5- or 6-membered heteroaryl in their turn can in each case be substituted once or twice in an identical or different manner by fluorine, chlorine, bromine, cyano, (C_1-C_6)-alkyl, hydroxyl, (C_1-C_4)-alkoxy, trifluoromethoxy, oxo, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl,

wherein (C_1-C_6)-alkyl in its turn can be substituted up to three times in an identical or different manner by fluorine, hydroxyl, (C_1-C_4)-alkoxy, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl, (C_1-C_4)-alkoxycarbonyl, (C_3-C_6)-cycloalkyl, 4- to 6-membered heterocycloalkyl, phenyl and/or 5- or 6-membered heteroaryl,

(*iii*) R^{10}, R^{11}, R^{17}, R^{19}, R^{28} and R^{30} independently of one another for each individual occurrence represent a radical chosen from the series consisting of hydrogen, (C_1-C_6)-alkyl, (C_3-C_6)-cycloalkyl and 4- to 6-membered heterocycloalkyl, wherein

(C_3-C_6)-cycloalkyl and 4- to 6-membered heterocycloalkyl in their turn can in each case be substituted up to three times in an identical or different manner by fluorine, (C_1-C_4)-alkyl, trifluoromethyl, hydroxyl, (C_1-C_4)-alkoxy, oxo, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-

alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl

and

(C_1-C_6)-alkyl can be substituted once to three times in an identical or different manner by fluorine, hydroxyl, (C_1-C_4)-alkoxy, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl, (C_1-C_4)-alkoxycarbonyl, (C_3-C_6)-cycloalkyl, 4- to 6-membered heterocycloalkyl, phenyl and/or 5- or 6-membered heteroaryl,

(*iv*) R^{12}, R^{16}, R^{18} and R^{31} independently of one another for each individual occurrence represent a radical chosen from the series consisting of hydrogen and (C_1-C_6)-alkyl,

wherein (C_1-C_6)-alkyl can be substituted once or twice in an identical or different manner by fluorine, hydroxyl, (C_1-C_4)-alkoxy, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl,

and/or wherein

(*v*) R^{11} and R^{12}, R^{16} and R^{17}, R^{18} and R^{19} and R^{30} and R^{31} in each case paired together with the atoms to which they are bonded can form a 5- or 6-membered heterocycloalkyl ring, which can be substituted once or twice in an identical or different manner by fluorine, (C_1-C_4)-alkyl, trifluoromethyl, hydroxyl, (C_1-C_4)-alkoxy, oxo, amino, mono-(C_1-

C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl,

and

J denotes O or S,


and

R^3 represents hydrogen,

and their salts, solvates and solvates of the salts.

14. A compound of the formula (I) as claimed in claim 11, in which

R^1 represents a heteroaryl group of the formula




wherein

* denotes the linkage point with the dihydropyrazolone ring


and

R^4 denotes hydrogen, fluorine, chlorine, bromine, cyano, (C_1-C_4)-alkyl, trifluoromethyl, hydroxymethyl, (C_1-C_4)-alkoxy, trifluoromethoxy, hydroxycarbonyl or (C_1-C_4)-alkoxycarbonyl,

R^2 represents a heteroaryl group of the formula



or



wherein

# denotes the linkage point with the dihydropyrazolone ring

and

R^6, R^{6A} and R^{6B} are identical or different and independently of one another denote hydrogen or a substituent chosen from the series consisting of fluorine, chlorine, bromine, cyano, (C_1-C_6)-alkyl, trifluoromethyl, hydroxyl, (C_1-C_6)-alkoxy, trifluoromethoxy, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl, (C_1-C_4)-alkoxycarbonyl and 4- to 6-membered heterocycloalkyl, wherein

(C_1-C_6)-alkyl in its turn can be substituted by hydroxyl, (C_1-C_4)-alkoxy or amino

and


4- to 6-membered heterocycloalkyl in its turn can be substituted once or twice in an identical or different manner by fluorine, cyano, (C_1-C_4)-alkyl, trifluoromethyl, hydroxyl, (C_1-C_4)-alkoxy, oxo, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, hydroxycarbonyl and/or (C_1-C_4)-alkoxycarbonyl,

and

R^3 represents hydrogen,

and their salts, solvates and solvates of the salts.

15. 2-[5-(Hydroxymethyl)pyridin-2-yl]-4-[4-(trifluoromethyl)-1*H*-imidazol-1-yl]-1,2-dihydro-3*H*-pyrazol-3-one according to Claim 11 having the following formula




and its salts, solvates and solvates of the salts.

16. A pharmaceutical composition comprising a compound according to Claim 11 and an inert, non-toxic, pharmaceutically suitable auxiliary substance.


17. A pharmaceutical composition comprising the compound according to Claim 15 and an inert, non-toxic, pharmaceutically suitable auxiliary substance.

18. A pharmaceutical composition comprising a compound according to Claim 11 and one or more additional active compounds chosen from the group consisting of ACE inhibitors, angiotensin II receptor antagonists, beta receptor blockers, calcium antagonists, PDE inhibitors, mineralocorticoid receptor antagonists, diuretics, aspirin, iron supplements, vitamin B12 and folic acid supplements, statins, tumor chemotherapeutics and antibiotics.

19. 2-[5-(Hydroxymethyl)pyridin-2-yl]-4-[4-(trifluoromethyl)-1*H*-imidazol-1-yl]-1,2-dihydro-3*H*-pyrazol-3-one according to Claim 11 having the following formula




20. 2-[5-(Hydroxymethyl)pyridin-2-yl]-4-[4-(trifluoromethyl)-1*H*-imidazol-1-yl]-1,2-dihydro-3*H*-pyrazol-3-one hydrochloride according to Claim 11 having the following formula



21. A pharmaceutical composition comprising the compound according to Claim 19 and an inert, non-toxic, pharmaceutically suitable auxiliary substance.

22. A pharmaceutical composition comprising a compound according to Claim 20 and an inert, non-toxic, pharmaceutically suitable auxiliary substance.

23. A process for the preparation of a compound of the formula (I) as defined in Claim 11, characterized in that a compound of the formula (II)




(II),

in which R^1 and R^3 in each case have the meanings given in Claim 11 and

Z^1 represents methyl or ethyl,


is reacted in an inert solvent, optionally in the presence of an acid, with a compound of the formula (III)



(III),

in which R^2 has the meaning given in Claim 11,

to give compounds of the formula (IV)




(IV)

in which Z^1, R^1, R^2 and R^3 have the meaning given in Claim 11,

which cyclize already under these reaction conditions or in a subsequent reaction step under the influence of a base to give the compounds of the formula (I),

and the compounds of the formula (I) are optionally converted with the corresponding (i) solvents and/or (ii) bases or acids into their solvates, salts and/or solvates of the salts.

24. A process for the preparation of a compound of the formula (I) as defined in Claim 11 in which R^3 denotes hydrogen, characterized in that a compound of the formula (V)




(V),

in which R^1 has the meaning given in Claim 11 and

Z^1 represents methyl or ethyl,

is subjected to a condensation reaction with a compound of the formula (VI)




(VI),

in which

Z^2 represents methyl or ethyl,


to give compounds of the formula (VII)



(VII),

in which Z^1 and R^1 have the meaning given in Claim 11,


and these are subsequently reacted in the presence of an acid with a compound of the formula (III)



(III),

in which R^2 has the meaning given in Claims 11,

to give compounds of the formula (IV-A)



(IV-A)

in which Z^1, R^1 and R^2 have the meaning given in Claim 11,

which cyclize already under these reaction conditions or in a subsequent reaction step under the influence of a base to give the compounds of the formula (I) wherein R^3 represents hydrogen.